July 5, 2017 / 12:20 PM / 2 months ago

BRIEF-Celsion announces completion of ovation study

July 5 (Reuters) - Celsion Corp

* Celsion announces completion of ovation study and provides update on its immunotherapy trial in advanced stage III and IV ovarian cancer

* Celsion Corp - ‍86 percent Objective Response Rate (ORR) in phase IB dose escalating study​

* Celsion Corp - ‍100 percent ORR and 100 percent R0 (margin negative) surgical resection rate at highest dose cohort​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below